Coleman, R. L., Lorusso, D., Gennigens, C., González-Martín, A., Randall, L., Cibula, D., Lund, B., Woelber, L., Pignata, S., Forget, F., Redondo, A., Vindeløv, S. D., Chen, M., Harris, J. R., Smith, M., Nicacio, L. V., Teng, M. S. L., Laenen, A., Rangwala, R., Manso, L., Mirza, M., Monk, B. J., Vergote, I., , , Raspagliesi, F., Melichar, B., Gaba Garcia, L., Jackson, A., Henry, S., Kral, Z., Harter, P., De Giorgi, U., Bjurberg, M., Gold, M., O'Malley, D., Honhon, B., Vulsteke, C., De Cuypere, E., Denys, H., Baurain, J., Zamagni, C., Tenney, M., Gordinier, M., Bradley, W., Schlumbrecht, M., Spirtos, N., Concin, N., Mahner, S., Scambia, G., Leath, C., Farias-Eisner, R., Cohen, J., Muller, C., & Bhatia, S. (2021). efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet oncology, 22(5), 609–619. http://access.bl.uk/ark:/81055/vdc_100129544568.0x000014